A team at Children’s National Research and Innovation Campus is working on something new that could change the way we pinpoint pain, and how effectively we treat it. The technology could give hope to ...

Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower ...

Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with ...

Vertex's closely watched drug, suzetrigine, reduced sciatica pain compared to baseline but did not outperform a placebo ...

US biopharma Vertex Pharmaceuticals today announced results from its Phase II study of suzetrigine, an investigational, oral, ...

Struggling with worst-case thinking? Discover the roots of catastrophizing, its link to past experiences, and strategies to ...

A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls ...

In a small clinical study, researchers in the US examined the nature of new-onset pain reported by people with long COVID and explored potential associations between long COVID symptoms and pain.

A new, presumably more precise or, hopefully, more relevant, pain scale, named the Detroit Interventional Pain Management ...